Androgen receptor antagonists - Pipeline Insight, 2024

Androgen receptor antagonists - Pipeline Insight, 2024

DelveInsight’s, “Androgen receptor antagonists - Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Androgen receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Androgen receptor antagonists Understanding

Androgen receptor antagonists: Overview

The androgen receptor (AR) pathway is emerging as a potential therapeutic target in breast cancer. AR-targeted drugs have been approved for treatment of prostate cancer; however, AR-targeted treatment for breast cancer is an area of active investigation.

Androgen receptor consists of 4 domains, an N-terminal domain, a DNA-binding domain, a hinge, and a ligand-binding domain, and functions as a nuclear transcription factor.9 In the absence of ligand, AR attaches to heat shock proteins and is located mainly in the cytoplasm.10 In the presence of ligand, the ligand-binding domain is unbound from heat shock protein and AR translocates into the nucleus, where the DNA-binding domain binds to androgen responsive elements inDNA and recruits additional coactivators, corepressors, and transcriptional modulators.

The AR antagonists, which are among the therapeutic agents most commonly used to treat prostate cancer, include several categories of drugs, for example, AR antagonists and CYP17A antagonists.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Androgen receptor antagonists R&D. The therapies under development are focused on novel approaches for Androgen receptor antagonists.

Androgen receptor antagonists Emerging Drugs Chapters

This segment of the Androgen receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Androgen receptor antagonists Emerging Drugs

• Enzalutamide: Pfizer

Enzalutamide acts as androgen receptor antagonists. It is approved for Prostate cancer. It is currently in phase II for, breast cancer, ovarian cancer, salivary gland cancer and is being developed by Pfizer in collaboration with Astellas Pharma.

In order to promote the advancement of scientific knowledge concerning the mechanisms of action, underlying biology, and clinical effectiveness of enzalutamide in prostate cancer, the National Comprehensive Cancer Network (NCCN), Pfizer Global Medical Grants (Pfizer) and Astellas Pharma Global Development (Astellas) are collaborating.

• TRC-253: Tracon Pharmaceuticals

TRC253 is a novel, orally bioavailable small molecule discovered and developed by Janssen Pharmaceutica that is a potent, high affinity competitive inhibitor of the androgen receptor (AR). TRC253 is intended to address resistance mechanisms to current AR inhibitors by specifically targeting mutations in the AR ligand binding domain. TRC253 also potently inhibits signalling through the wild type AR. These susceptible AR mutations have been identified using circulating tumor DNA assays, potentially allowing for selected patient biomarker-directed therapy. It is being developed by Tracon Pharmaceuticals in collaboration with Janssen Pharmaceutica.

It is currently in phase II stage of development for the treatment of Prostate cancer.

Further product details are provided in the report……..

Androgen receptor antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Androgen receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on Androgen receptor antagonists

There are approx. 20+ key companies which are developing the Androgen receptor antagonists. The companies which have their Androgen receptor antagonists drug candidates in the most advanced stage, i.e. Phase II include, Pfizer.

• Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Androgen receptor antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Androgen receptor antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Androgen receptor antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Androgen receptor antagonists drugs.

Androgen receptor antagonists Report Insights

• Androgen receptor antagonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Androgen receptor antagonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Androgen receptor antagonists drugs?
• How many Androgen receptor antagonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Androgen receptor antagonists?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Androgen receptor antagonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Androgen receptor antagonists and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Tracon Pharmaceuticals
• MAIA Biotechnology
• Xennials Therapeutics
• Pfizer
• Chia Tai Tianqing Pharmaceutical Group
• ESSA Pharma
• Novan

Key Products

• TRC-253
• MJC13
• XNTR-955
• XNTR-934
• XNTR-936
• Enzalutamide
• TQB3720
• EPI-7386
• SB-206